Novavax News

Novavax | 8-K: Investor Presentation

Nov 21 01:57

Novavax | 8-K: U.S. FDA Removes Clinical Hold on Novavax's COVID-19-Influenza Combination and Stand-alone Influenza Phase 3 Trial

Nov 13 00:24

Novavax | 8-K: Settlement Agreement

Nov 6 06:06

Novavax | 8-K: Update on Novavax's COVID-19-Influenza Combination and Stand-alone Influenza Phase 3 Trial

Oct 16 20:02

Novavax | 8-K: Regulation FD Disclosure

Oct 4 02:51

Novavax | S-8: Initial registration statement for securities to be offered to employees pursuant to employee benefit plans

Aug 9 04:21

Novavax | 8-K: Poll Results of 2024 Stockholders Meeting

Jun 15 04:07

Novavax | 8-K: Investor Presentation of Novavax, Inc.

Jun 6 19:01

Novavax | DEFA14A: Others

Jun 5 18:06

Novavax | 8-K: R&D President Filip Dubovsky Resigns

May 24 04:12

Novavax | DFAN14A: Definitive additional proxy soliciting materials filed by non-management

May 21 02:45

Novavax | DFAN14A: Definitive additional proxy soliciting materials filed by non-management

May 14 04:15

Novavax | 8-K: Collaboration and License Agreement

May 14 02:44

Novavax | DFAN14A: Definitive additional proxy soliciting materials filed by non-management

May 9 04:57

Novavax | DFAN14A: Definitive additional proxy soliciting materials filed by non-management

May 8 05:26

Novavax | DFAN14A: Definitive additional proxy soliciting materials filed by non-management

May 7 04:45

Novavax | DEFA14A: Others

Apr 29 20:03

Novavax | DEF 14A: Definitive information statements

Apr 29 19:57

Novavax | 8-K: Current report

Apr 27 04:39

Novavax | 8-K: Confidential Settlement Agreements and Release Agreements

Mar 27 04:07